Abstract

This study was approved on 04/30/2012 and is currently enrolling patients. Enrollment is currently 44% to completion. No safety and tolerability events have occurred to affect progression of the study. The study remains blinded, and therefore no additional detail or analysis will be available until after the completion of the dose escalation. Details of the study are posted at ClinicalTrial.gov http://clinicaltrials.gov/ct2/show/NCT01597401 and at the NIH Clinical Center web site: http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_12-H-0127.htmlaes-103

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAHL006149-02
Application #
8746698
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2013
Total Cost
$470,922
Indirect Cost

  Institution

Name
National Heart, Lung, and Blood Institute
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Fertrin, Kleber Y; Samsel, Leigh; van Beers, Eduard J et al. (2016) Sickle Cell Imaging Flow Cytometry Assay (SIFCA). Methods Mol Biol 1389:279-92
Oder, Esther; Safo, Martin K; Abdulmalik, Osheiza et al. (2016) New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol 175:24-30
Safo, Martin K; Kato, Gregory J (2014) Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am 28:217-31